Friday, July 10, 2026

pharma · Primary Sclerosing Cholangitis (PSC) · No medical condition.

Dr. Falk Pharma

Dr. Falk Pharma is a pharma organization headquartered in Freiburg im Breisgau, DE. Primary therapeutic focus areas include Primary Sclerosing Cholangitis (PSC), No medical condition., eosinophilic esophagitis, Celiac Di

Leinenweberstraße 5, Freiburg im Breisgau, Baden-Württemberg 79108, DE HQ
399 Employees
EMA registrant Type
Company details
Status
Public
HQ
Leinenweberstraße 5, Freiburg im Breisgau, Baden-Württemberg 79108, DE
Employees
399
Programs
11
Drugs
15
Patents
0
Clinical program

NAT-022/BIO

Phase 1 · other · Idiopathic or diabetic gastroparesis

NAT-022/BIO for Idiopathic or diabetic gastroparesis is a Phase 1 program (other) at Dr. Falk Pharma GmbH with 1 ClinicalTrials.gov record(s).

Internal code NAT-022/BIO

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Dr. Falk Pharma GmbH
Phase
Phase 1
Modality
other
Indication
Idiopathic or diabetic gastroparesis
Status
active
Trials
1